

# Assessment of the health impact of the industrial emissions in the environmental management of the "Taranto Case"

**Prof. Giorgio Assennato**Direttore Generale ARPA - Puglia




TARANTO (Pop. 192,810), Apulia, S Italy, on the Gulf of Taranto, an arm of the Ionian Sea.


Taranto is the chief military port of Italy. It is also an industrial, and fishing center. Productions include steel, metal products, refined petroleum, cement, machinery, and ships.



Founded by the Spartans, according to tradition (8th century BC.) ,it became one of the most prosperous cities in Magna Græcia. (Great Greece), and is now site of several historical tourist attractions, including a national museum, a theater etc.

It was built up on the extreme eastern side of the Isthmus, which was joined to the Peninsula Salentina continent, on the coastal road along Mare Grande (Big Sea) and an ample lagoon called Mare Piccolo (Small Sea) (that's why Taranto is named "the City with Two Seas").









#### **Particulate matter Guideline values**

#### **PM2.5**

10 μg/m3 annual mean

25 μg/m3 24-hour mean


#### **PM10**


20 μg/m3 annual mean

50 μg/m3 24-hour mean

The 2005 AQG set for the first time a guideline value for particulate matter (PM). The aim is to achieve the lowest concentrations possible. As no threshold for PM has been identified below which no damage to health is observed, the recommended value should represent an acceptable and achievable objective to minimize health effects in the context of local constraints, capabilities and public health priorities.

Fig.1. Percentage of people living in cities with various PM10 levels in  $\mu g/m3$ , 2009





EXPOSURE TO PARTICULATE AIR POLLUTION AND RISK OF DEEP VEIN THROMBOSIS Baccarelli A, Martinelli I, Zanobetti A, et al. Arch Intern Med 2008; 168:920-927

# CONCENTRATION-RESPONSE FACTORS FOR HUMAN HEALTH EFFECTS ASSOCIATED WITH PM10

Annual risk factor given a 1 ug/m3 change in annual average PM10 concentration:

Mortality risk: 1.80E-05

**Chronic bronchitis risk:** 6.10E-05 [for population 25 years and older]

**Respiratory hospital admissions:** 8.40E-06

Cardiac hospital admissions: 3.00E-06

**Emergency room visits:** 2.40E-04

Asthma symptom days: 5.80E-02 [for 4.7% of population with asthma]


**Restricted activity days:** 5.80E-02 [for population 18 years and older]



Investigating the Health Impact of Emissions to Air from Local Industry

#### Contents

	Page
Foreword	"
Part One	1-6
Background	1-4
A Staged Approach to Investigations	4-6
Part Two	7-17
Stage 1: preliminary investigation	7-9
Stage 2: examination of the environmental data	10
Stage 3: examination of the local health profile	11-12
Stage 4: a detailed assessment of emissions	13-15
Stage 5: a more detailed investigation or study	16-17
Part Three	18-22
Who should do what?	18
Handling the Outcome of Investigations	19-20
Should there be a health study?	20-21
The lessons learned	22
Appendices	23-54
Appendix 1: The regulatory regimes	23-32
Appendix 2: Health authorities and Integrated Pollution	
Prevention Control	33-35
Appendix 3: Interpreting routinely available data on respiratory	
disease in the light of environmental health concerns	36-44
Appendix 4: Useful Addresses and websites	45-50
Appendix 5: Reports and references	51-54



Orru H, Teinemaa E, Lai T, Tamm T, Kaasik M, Kimmel V, Kangur K, Merisalu E, Forsberg B.

# Health impact assessment of particulate pollution in Tallinn using fine spatial resolution and modeling techniques.

Environmental Health. 2009;8:7





Figure I Modeled (200 × 200 m grid) annual average concentration of PM<sub>2.5</sub> in Tallinn, μg/m<sup>3</sup>.

#### The number of premature death due to PM2.5 pollution in Tallinn

City district	Number of population	Annual exposure to local PM2.5 (µg/m3)	Number of Premature deaths (95% CI)	Number of premature deaths 1/1000 (95% CI)	The loss of life expectancy in years (95% CI)
Haabersti	38 031	9.5	23 (6–42)	0.60 (0.16–1.10)	0.52 (0.14–0.90)
Mustamäe	62 589	14.0	63 (16–112)	1.01 (0.26–1.79)	0.78 (0.20–1.34)
Nõmme	38 268	7.2	18 (5–31)	1.01 (0.26–1.79)	0.78 (0.20–1.34)
Kesklinn	47 105	17.1	51 (13–91)	1.08 (0.28–1.93)	0.94 (0.25–1.62)
Kristiine	28 878	16.2	30 (8–54)	1.04(0.28–1.87)	0.89 (0.24–1.53)
Lasnamäe	107 280	10.2	73 (19–131)	0.68 (0.18–1.22)	0.56 (0.15–0.97)
Pirita	13 192	6.4	5 (1–8)	0.38 (0.08–0.61)	0.36 (0.09–0.61)
Põhja- Tallinn	53 621	9.3	33 (9–59)	0.62 (0.17–1.10)	0.52 (0.14–0.89)
TOTAL	388 964	11.6	296 (76–528)	0.76 (0.20–1.36)	0.64 (0.17–1.10)






Figure 4
Decrease of life-expectancy due to PM<sub>2.5</sub> pollution in Tallinn.





Figure 3
The total number of YLL due to PM<sub>2.5</sub> pollution in Tallinn.

#### Benzo[a]pirene Rilevation- 2009

Medie aritmetiche e pesate dei valori di concentrazione mensile di b(a)p in ng/mc nei 3 siti di Taranto

VIA MACHIAVELLI	VIA ALTO ADIGE	TALSANO
media pesata	media pesata	media pesata
1.31	0.36	0.35
media aritmetica	media aritmetica	media aritmetica
1.39	0.39	0.38

#### Andamento mensile di concentrazione di benzo(a)pirene



## Estimate of cancer risk



- ➤ BaP in class 1/ARC carcinogenic for humans
- > Uncertainty about the quantitative estimate and the risk and the dose-response relationship
- ➤ PAHs are a mixture, which the different components have different potential carcinogen, BaP used as a substance index
- Revision of estimates available in the literature:

Basis for calculation	Unit risk	Reference
Animal experiments	1000	
Inhalation of B[a]P in hamsters (Thyssen et al. 1981)	$0.28 \times 10^{-6}$ a	RIVM (1989)
Inhalation of B[a]P in hamsters (Thyssen et al. 1981)	$0.37-1.7 \times 10^{-6 b}$	CARB (1994); Collins et al. (1991); Muller (1997)
Inhalation of B[a]P + SO <sub>2</sub> in rats (Laskin et al. 1970 cit. RIVM 1989)	$0.59 \times 10^{-6}$	RIVM (1989)
Inhalation of B[a]P in mice (Knizhikow et al. 1982 cit. RIVM 1989)	$400 \times 10^{-6} a$	RIVM (1989)
Intratracheal instillation of B[a]P in hamsters		
Saffiotti et al. (1972)	4.4 × 10-6 b	CARE (1994); Collins et al. (1991)
Feron et al. (1973)	$4.8 \times 10^{-6} h$	CARE (1994); Collins et al. (1991)
Inhalation of coal tar/pitch aerosol with B[a]P as the indicator substance	$20 \times 10^{-6}  b$	Heinrich et al. (1994)
Epidemiology (PAH with B[a]P as indicator		
U.S. coke-oven workers	$87 \times 10^{-6}$	WHO (1987, 2000)
U.S. coke-oven workers	$23 \times 10^{-6}$	Muller (1997)
U.S. coke-oven workers	$50 \times 10^{-6}$	Pott (1985)
U.K. gas workers	$430 \times 10^{-6}$	Pike (1983)
Smoky coal indoors in China	$67 \times 10^{-6}$	RIVM (1989)
Most appropriate estimate	$100 \times 10^{-6}$	RIVM (1989)
Aluminum smolters	90 × 10 <sup>-6</sup>	Armstrong et al. (1994); converted from workplace exposure to continuous lifetime exposure

# Estimation of B(a)P related



# carcinogenic risk

# Estimated health impact on the population of the district-TamburiLido Azzurro in Taranto

Starting from the average concentration of BaP detected at the site of via Machiavelli in Taranto in 2010 (1.82 ng/m3) and using the unit risk value indicated by the WHO (8.7 x 10-5 to 1 ng/m3 BaP), an incremental risk was estimated being equal to:

Incremental Lifetime Cancer Risk =  $8.7 \times 10^{-5} (ng/m^3) \times 1.82 (ng/m^3) = 15.8 \times 10^{-5}$ 

Estimated excess of cases of lung cancer in the population of the district-Tamburi Lido Azzurro (17,644 inhabitants on April 9, 2009) due to a lifetime exposure at the measured level of BaP, is equal to:

 $15.8 \times 10^{-5} \times 17644 = 2.79$  cancers

## Estimate of cancer risk



US –EPA considers excess cancer risks that are below about 1 chance in 1,000,000 ( $1\times10^{-6}$  or 1E-06) to be so small as to be negligible, and risks above 1E-04 to be sufficiently large that some sort of remediation is desirable

Risk Assessment Guidance for Superfund, 1989

Figure 2-1. Risk Assessment Approach




Table 3-3. Summary of Cancer Risk Assessment Screening Analysis

Constituent	AK Steel Middletown	AK Steel Ashland	Erie Coke	Tonawanda
Benzo(a)pyrene	2x 10 <sup>-10</sup>	4x10 <sup>-9</sup>	2x 10 <sup>-10</sup>	2x 10°10
Benzo(a)anthracene	2x 10 <sup>-10</sup>	4x10 <sup>-9</sup>	3x 10 <sup>-10</sup>	2x 10 <sup>-11</sup>
Benzene	2x10 <sup>-5</sup>	5x10 <sup>-4</sup>	7x10 <sup>-6</sup>	5x10 <sup>-5</sup>
Benzene soluble organics	5x10 <sup>-5</sup>	$8 \times 10^{-4}$	2x10 <sup>-4</sup>	1x10 <sup>-4</sup>
Benzo(b)fluoranthene	2x 10 <sup>-10</sup>	4x10 <sup>-9</sup>	2x 10 <sup>-10</sup>	4x 10 <sup>-11</sup>
Benzo(k)fluoranthene	1x10 <sup>-10</sup>	2x10 <sup>-9</sup>	2x 10 <sup>-10</sup>	2x 10 <sup>-13</sup>
Chrysene	6x 10 <sup>-11</sup>	1x10 <sup>-9</sup>	7x 10°11	6x 10 <sup>-12</sup>
Nickel	2x10 <sup>-9</sup>	4x10 <sup>-8</sup>	3x 10 <sup>-9</sup>	6x 10 <sup>-10</sup>
Arsenic	3x10 <sup>-8</sup>	6x10 <sup>-7</sup>	3x 10 <sup>-8</sup>	2x10 <sup>-8</sup>
Beryllium	5x 10 <sup>-10</sup>	1 x 10 <sup>-8</sup>	6x 10 <sup>-10</sup>	1x10 <sup>-10</sup>
Cadmium	2x10 <sup>-9</sup>	4x10 <sup>-8</sup>	2x10 <sup>-9</sup>	9x 10 <sup>-10</sup>
Total	7x10 <sup>-5</sup>	1x10 <sup>-3</sup>	2x10 <sup>-4</sup>	2x10 <sup>-4</sup>

Table 3-10. Inhalation Cancer Risk and Hazard Quotient for Exposed Population


Site	Facility-Level Maximum Risk <sup>a</sup>	Hazard Quotient
AK Steel-Middletown	5x10 <sup>-5</sup>	$NI^b$
477.6	5 10-4	Benzene → 0.4
AK Steel-Ashland	$5 \times 10^{-4}$	Arsenic →0.07
Erie Coke	1x10 <sup>-4</sup>	NI
Tonawanda	$1 \times 10^{-4}$	NI

<sup>&</sup>lt;sup>a</sup> Maximum risk at 70 year exposure duration

Results reflect exposure from all emission sources, (i.e., MACT I, MACTII, and the By-Product Recovery Plant)

<sup>&</sup>lt;sup>b</sup> NI = not included in analysis

Figure 3-1 Cancer Risk Isopleths Around AK-Steel Middletown






Figure 3-3 Cancer Risk Isopleths Around Erie Coke





Figure 3-4 Cancer Risk Isopleths Around Tonawanda Coke



Simulation of PM10 concentration of industry and residents




Tabella 13. Associazione tra esposizione a polveri inquinanti (PM<sub>10</sub> proveniente dalla zona industriale) e mortalità per causa. Rischio relativo per 10 ° g/m³ PM<sub>10</sub>

Course (ICD o CM)		Maschi*		Femmine**			
Causa (ICD-9-CM)	HR	Low	Up	HR	Low	Up	
Tutte le cause (001-999)	1,02	1,00	1,05	1,01	0,99	1,03	
Cause naturali (001-799)	1,03	1,00	1,05	1,00	0,98	1,02	
Turnori maligni (140-208)	1,01	0,97	1,05	0,98	0,94	1,01	
Esofago (150)	1,38	0,95	2,02	0,73	0,41	1,31	
Stomaco (151)	1,03	0,87	1,22	1,07	0,93	1,23	
Colon retto (153-154)	0,85	0,72	1,00	0,90	0.80	1,00	
Fegato e dotti biliari (155-156)	0,84	0,71	0,99	0,99	0,89	1,10	
Pancreas (157)	1,15	0,95	1,39	1,02	0,89	1,16	
Laringe (161)	0,87	0,64	1,17				
Trachea, bronchi e polmoni (162)	1,02	0,95	1,09	0,97	0,85	1,10	
Pleura (163)	1,12	0,90	1,38	1,00	0,73	1,37	
Connettivo e tessuti molli (171)	1,53	1,01	2,31	0,80	0,48	1,34	
Mammella (174)				1,04	0,96	1,13	
Prostata (185)	1,14	1,01	1,28	200			
Testicolo (186)	0,56	0,16	1,97				
Vescica (188)	1,00	0,86	1,15	1,12	0,91	1,38	
Rene (189)	0,98	0,64	1,50	0,78	0,44	1,39	
Encefalo ed altri tumori del SNC (191-192; 225)	1,08	0,88	1,33	0,83	0,68	1,01	
Tessuto linfatico ed ematopoietico (200-208)	1,05	0,91	1,22	0,90	0,80	1,02	
Linfomi non-Hodgkin (200-202)	1,09	0,86	1,39	0,90	0,73	1,11	
Leucemie (204-208)	1,04	0,81	1,33	0,94	0,77	1,15	
Malattie neurologiche (330-349)	1,05	0,91	1,22	1,09	1,00	1,19	
Morbo di Parkinson (332)	1,12	0,83	1,50	0,90	0,69	1,17	
Malattie cardiovascolari (390-459)	1,01	0,97	1,05	1,01	0,98	1,03	
Malattie cardiache (390-429)	1,02	0,98	1,07	1,05	1,01	1,08	
Malattie ischemiche del cuore (410-414)	1,06	0,99	1,14	1,11	1,06	1,18	
Eventi coronarici acuti (410-411)	1,06	0,96	1,18	1,11	1,02	1,20	
Malattie cerebro-vascolari (430-438)	0,96	0,88	1,05	0.90	0,85	0,95	
Malattie apparato respiratorio (460-519)	0,97	0,90	1,04	1,00	0,94	1,07	
Infezioni delle vie respiratorie (460-466,480-487)	0,91	0,77	1,07	0,95	0,85	1,06	
BPCO (490-492, 494, 496)	0,97	0,89	1,06	1,02	0,93	1,11	
Malattie apparato digerente (520-579)	1,04	0,96	1,13	0.97	0,90	1,03	
Malattie renale (580-599)	1,10	0,95	1,29	1,10	1,00	1,22	

## Association between primary industrial PM10 and hospital cases. Relative risk by 10 µg/cubic meter

hospital cases. Relative risk by 10 μg/cubic meter		MALES			FEMALES		
		HR	LOW	UP	HR	LOW	UP
Pop AGE 0-14							
cancer	(140-208)	1,25	0,91	1,71	1,27	0,89	1,80
diseases of the respiratory tract	(460-519)	1,09	1,05	1,12	1,09	1,05	1,13
respiratory tract infections	(460-466,480-487)	1,12	1,08	1,16	1,12	1,07	1,17
Asthma	(493)	0,79	0,62	1,02	0,70	0,49	1,00


Forastiere et al.2012

Hazard Ratio (HR), Cox model stratified by follow-up period, adjusted by age and socioeconomic status

### Number of attributable cases (and AR%) to industrial primary PM10for hospital cases (1998-2010)

	Total	Attributable	0	
	iotai	Attributable	<b>C</b>	
	cases	cases	95% CI	AR %
(140-208)	89	17	0-35	19.5
(460-519)	8769	638	456-820	7.3
(460-466,480-487)	6281	627	478-776	10.0
	(460-519)	(140-208) 89 (460-519) 8769	(140-208) 89 17 (460-519) 8769 638	(140-208) 89 17 0-35 (460-519) 8769 638 456-820

Forastiere et al.2012



# Environment and Health in Taranto: a proposal of ARPA Puglia and ASL to national department of Environment during the IPPC process

- 1. Source apportionment of atmospheric PM10 PM2.5 and its deposition;
- 2. Biomonitoring of PAH and heavy metal exposure in general population of Taranto, at different distance from industrial area;
- 3. Short-term effects of pollution on human health;
- 4. Long-term effects of pollution on human health;
- 5. Case-control study on non Hodgkin lymphomas, soft tissue sarcomas and exposure to PCDD/Fs and PCB.



# Grazie per l'attenzione